CA2943098C - Fused imidazobenzothiazole compounds - Google Patents

Fused imidazobenzothiazole compounds Download PDF

Info

Publication number
CA2943098C
CA2943098C CA2943098A CA2943098A CA2943098C CA 2943098 C CA2943098 C CA 2943098C CA 2943098 A CA2943098 A CA 2943098A CA 2943098 A CA2943098 A CA 2943098A CA 2943098 C CA2943098 C CA 2943098C
Authority
CA
Canada
Prior art keywords
alkyl
imidazo
pyrazol
tert
benzothiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2943098A
Other languages
English (en)
French (fr)
Other versions
CA2943098A1 (en
Inventor
Pundlik SHINDE
Sanjay Srivastava
Davindar TULI
Deepak Rai
Prashant GJ
Shailesh Deshpande
Rameshchandra GUPTA
Vijay Chauthaiwale
Chaitanya Dutt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of CA2943098A1 publication Critical patent/CA2943098A1/en
Application granted granted Critical
Publication of CA2943098C publication Critical patent/CA2943098C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CA2943098A 2014-03-27 2015-03-24 Fused imidazobenzothiazole compounds Active CA2943098C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1089MU2014 2014-03-27
IN1089/MUM/2014 2014-03-27
PCT/IB2015/052124 WO2015145336A1 (en) 2014-03-27 2015-03-24 Novel fused imidazobenzothiazole compounds

Publications (2)

Publication Number Publication Date
CA2943098A1 CA2943098A1 (en) 2015-10-01
CA2943098C true CA2943098C (en) 2022-07-05

Family

ID=54194050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2943098A Active CA2943098C (en) 2014-03-27 2015-03-24 Fused imidazobenzothiazole compounds

Country Status (30)

Country Link
US (2) US9908898B2 (enExample)
EP (1) EP3122755B1 (enExample)
JP (1) JP6480949B2 (enExample)
KR (1) KR102339610B1 (enExample)
CN (1) CN106414458B (enExample)
AR (1) AR099867A1 (enExample)
AU (1) AU2015237840B2 (enExample)
CA (1) CA2943098C (enExample)
CY (1) CY1121147T1 (enExample)
DK (1) DK3122755T3 (enExample)
EA (1) EA029745B9 (enExample)
ES (1) ES2707099T3 (enExample)
HR (1) HRP20190121T1 (enExample)
HU (1) HUE042493T2 (enExample)
IL (1) IL247955B (enExample)
LT (1) LT3122755T (enExample)
MX (1) MX368985B (enExample)
MY (1) MY193041A (enExample)
PH (1) PH12016501903B1 (enExample)
PL (1) PL3122755T3 (enExample)
PT (1) PT3122755T (enExample)
RS (1) RS58324B1 (enExample)
SG (1) SG11201607793RA (enExample)
SI (1) SI3122755T1 (enExample)
SM (1) SMT201900036T1 (enExample)
TR (1) TR201900735T4 (enExample)
TW (1) TWI648282B (enExample)
UA (1) UA121469C2 (enExample)
WO (1) WO2015145336A1 (enExample)
ZA (1) ZA201606598B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
DE102016209204A1 (de) 2016-05-27 2017-11-30 Robert Bosch Gmbh Vorrichtung zur Regelung mindestens eines Fluidstroms in einem Fahrzeug
KR102630959B1 (ko) * 2016-10-31 2024-01-29 엘지디스플레이 주식회사 유기 화합물과 이를 이용한 발광다이오드 및 유기발광다이오드 표시장치
CN106727538A (zh) * 2017-02-20 2017-05-31 潘连香 一种治疗2型糖尿病的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724566D0 (en) * 1987-10-20 1987-11-25 Roussel Lab Ltd Chemical compounds
GB8908845D0 (en) * 1989-04-19 1989-06-07 Roussel Lab Ltd Chemical compounds
WO1995029922A1 (en) 1994-04-29 1995-11-09 Pharmacia & Upjohn Company Methanol derivatives for treatment of retroviral infections especially hiv infections
AU2001294515A1 (en) 2000-08-11 2002-02-25 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
MXPA05005474A (es) * 2002-11-25 2005-07-25 Pharmacia Corp Acidos y amidas heteroarilsulfonilmetil hidroxamicos y su uso como inhibidores de proteasas.
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
EP1984363A1 (en) * 2006-02-09 2008-10-29 Pfizer Limited Triazolopyridine compounds
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物

Also Published As

Publication number Publication date
MX368985B (es) 2019-10-23
TR201900735T4 (tr) 2019-02-21
CN106414458A (zh) 2017-02-15
UA121469C2 (uk) 2020-06-10
ES2707099T3 (es) 2019-04-02
SMT201900036T1 (it) 2019-02-28
PH12016501903B1 (en) 2019-04-26
AU2015237840A1 (en) 2016-09-29
EP3122755B1 (en) 2018-11-07
DK3122755T3 (en) 2019-02-18
SG11201607793RA (en) 2016-10-28
US10227361B2 (en) 2019-03-12
KR102339610B1 (ko) 2021-12-14
PH12016501903A1 (en) 2017-01-09
EA201691920A1 (ru) 2017-01-30
HUE042493T2 (hu) 2019-07-29
TW201613941A (en) 2016-04-16
AR099867A1 (es) 2016-08-24
LT3122755T (lt) 2019-02-11
IL247955A0 (en) 2016-11-30
JP6480949B2 (ja) 2019-03-13
ZA201606598B (en) 2017-11-29
WO2015145336A1 (en) 2015-10-01
US20180127437A1 (en) 2018-05-10
RS58324B1 (sr) 2019-03-29
EA029745B1 (ru) 2018-05-31
EA029745B9 (ru) 2018-08-31
PT3122755T (pt) 2019-01-30
MX2016012535A (es) 2017-05-04
SI3122755T1 (sl) 2019-02-28
JP2017513825A (ja) 2017-06-01
AU2015237840B2 (en) 2019-06-20
HRP20190121T1 (hr) 2019-03-08
US20170107233A1 (en) 2017-04-20
MY193041A (en) 2022-09-23
US9908898B2 (en) 2018-03-06
EP3122755A1 (en) 2017-02-01
IL247955B (en) 2021-02-28
TWI648282B (zh) 2019-01-21
CA2943098A1 (en) 2015-10-01
NZ724342A (en) 2021-02-26
CN106414458B (zh) 2019-10-29
KR20160129089A (ko) 2016-11-08
PL3122755T3 (pl) 2019-05-31
CY1121147T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
US10227361B2 (en) Fused imidazobenzothiazole compounds
US11802126B2 (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
JP2021505684A (ja) ヒストンデアセチラーゼ６阻害剤としての１，２，４−オキサジアゾール誘導体
EP2970306A1 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
TW202411233A (zh) 用於治療trpm3介導病症之新型衍生物
US20190127381A1 (en) Substituted fused pyrimidinone compounds
TW201317240A (zh) 用於治療疾病之組胺受體的雜環抑制劑
US9963463B2 (en) Urea-substituted indanes as P38 map kinase inhibitors
NZ724342B2 (en) Novel fused imidazobenzothiazole compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200115

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240925